Research Advances of JAK/STAT Signaling Pathway in Lung Cancer.
10.3779/j.issn.1009-3419.2019.01.09
- Author:
Xin YANG
1
;
Zhe TANG
2
;
Peng ZHANG
1
;
Li ZHANG
1
Author Information
1. Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
2. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Publication Type:Journal Article
- Keywords:
Drug resistance;
Inhibitors;
JAK/STAT signaling pathway;
Lung neoplasms
- MeSH:
Animals;
Antineoplastic Agents;
therapeutic use;
Biomedical Research;
methods;
trends;
Humans;
Janus Kinases;
antagonists & inhibitors;
metabolism;
Lung Neoplasms;
drug therapy;
metabolism;
pathology;
Neoplasm Metastasis;
STAT Transcription Factors;
antagonists & inhibitors;
metabolism;
Signal Transduction
- From:
Chinese Journal of Lung Cancer
2019;22(1):45-51
- CountryChina
- Language:Chinese
-
Abstract:
Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway is one of the downstream pathways of cytokine signaling transduction. It regulates cell development, differentiation, proliferation, apoptosis and so on. The pathway is not only involved in the regulation of normal physiological processes, but also significant in the development of tumors, especially in hematologic malignancies. In recent years, with the further research of JAK/STAT signaling pathway, it has been found that the pathway also plays a key role in the development of solid tumors. Here we reviewed the research advances of JAK/STAT signaling pathway in lung cancer, especially the mechanisms of development, metastasis and drug resistance, and the application of inhibitors which targeting JAK/STAT signaling pathway in the treatment of lung cancer.
.
